科勁國際(06822.HK)年度純利減少16.8%至9491萬港元 末期息6港仙
格隆匯3月21日丨科勁國際(06822.HK)公吿,截至2021年12月31日止年度,公司收益13.02億港元,同比減少0.7%;公司擁有人應占溢利9491萬港元,同比減少16.8%;每股盈利13.6港仙,董事議決建議派付每股6.0港仙的末期股息。
收益減少主要由於市場情緒及訂單逐步恢復,而於集團位於亞洲、歐洲及加拿大的目標市場逐步推出COVID-19疫苗接種計劃後,恢復情況愈加理想。然而,此裨益因美國品牌擁有人的保守作風而有所衝抵,原因為在全球供應鏈不穩定的情況下,產品面臨物流成本上漲,而COVID-19新變種病毒使產品需求的不明朗程度再添一層,導致客户下單時猶豫不決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.